CHARLESTON, W.Va. — Off-label uses of opioid products dominated testimony Friday in the ongoing trial pitting the state of West Virginia against three opioid manufacturers. The lawsuit alleges Johnson ...

NEW YORK, Nov. 11, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced that it has entered ...

This is the inaugural transaction in the European Loan Market, and first fundraising outside LATAM, for the Brazilian-founded multinational. The Company is expected to achieve ~€550 Million in revenue ...

Chaim Lebovits, President and CEO, stated that "our unwavering primary focus remains the execution of the clinical development plan for NurOwn and the initiation of our pivotal Phase 3b trial designed ...

Polyrizon Ltd., a biotech company developing innovative intranasal hydrogels, is preparing for a clinical trial of its PL-14 allergy blocker set for 2025. The company has partnered with Eurofins CDMO ...